# Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates

> **NCT04764851** · PHASE1 · TERMINATED · sponsor: **Emalex Biosciences Inc.** · enrollment: 30 (actual)

## Conditions studied

- Drug-Interactions

## Interventions

- **DRUG:** ecopipam HCl ~2mg/kg/day
- **COMBINATION_PRODUCT:** Cohort 1 Probe Cocktail
- **COMBINATION_PRODUCT:** Cohort 2 Probe Cocktail
- **COMBINATION_PRODUCT:** Cohort 3 Probe Cocktail

## Key facts

- **NCT ID:** NCT04764851
- **Lead sponsor:** Emalex Biosciences Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-02-18
- **Primary completion:** 2021-04-02
- **Final completion:** 2021-05-07
- **Target enrollment:** 30 (ACTUAL)
- **Why stopped:** A number of subjects withdrew consent leaving the study without adequate power to achieve its primary end points.
- **Last updated:** 2021-05-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04764851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04764851, "Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04764851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*